
Bridging the gap between unlicensed medicines and unmet need
Suzanne Aitken, Senior Vice President of Managed Access at Clinigen, discusses the benefits of unlicensed medicines (ULMs) and why regulators and the industry need to do more to improve patient access to these therapies. The pharmaceutical industry is constantly changing. However, an unwavering problem is the constant unmet need facing… Read More



